$ACTU

$0.53 +$0.05 (11.09%) Close

$ACTU Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 24.0M shares outstanding

Who owns ACTU?

By type of holder

Institutions 55.9% Insiders 44.2% Everyone else 0.0%

Concentration Top 10 holders own 286.8%

Aaron G.L. Fletcher 42.8% · Bios Advisors GP, LLC 42.4%

Institutional ownership

55.9%

-1.9 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

−445.7K

by institutions in Q2 2026

New / sold out

16 / 16

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Aqr Capital Management LLC +100.4K
Millennium Management LLC NEW +96.7K

Biggest sellers in Q2 2026

BlackRock, Inc. −337.1K
Geode Capital Management, LLC −115.8K

Who is planning to sell?

Notices of proposed sale, last 12 months

$2.13M

1 notice from 1 person

Shares covered

280.0K

1.17% of the company

Arranged in advance

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Kairos Venture Partners II, L.P. Affiliate $2.13M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+1365.0%

+282.75% a year

Each share's claim on the business

−93.2%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $8.47M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years94% Under 1 year6%

Quarterly turnover

5.4%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting ACTU on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BC BIOS Capital Management, LP 13D · 49.5%	10.0M	41.85%	Unchanged	2024	36.9%
Shares held by quarter Peak holding10.0M (Q3'25) Change over 8 quarters+10.0M Share of the company41.850% Disclosed stake13D · 49.5% BIOS Capital Management, LP's full portfolio →
VC Voss Capital, LP	1.7M	7.18%	Unchanged	2024	0.1%
Shares held by quarter Peak holding1.7M (Q1'26) Change over 8 quarters+1.7M Share of the company7.180% Voss Capital, LP's full portfolio →

BIOS Capital Management, LP

13D · 49.5%

10.0M

% of company

41.85%

Change vs last qtr

Unchanged

Held since

2024

Voss Capital, LP

1.7M

% of company

7.18%

Change vs last qtr

Unchanged

Held since

2024

28 more super investors behind a free account

See every manager holding Actuate Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ACTU on Form N-PORT; together they hold 3.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$440K	287.4K	1.20%	0.00%	June 30, 2026
FS Fidelity Small Cap Index Fund Fidelity Salem Street Trust	$272K	92.6K	0.39%	0.00%	April 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$440K

% of company

1.20%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Small Cap Index Fund

Fidelity Salem Street Trust

Position value

$272K

% of company

0.39%

% of the fund

0.00%

As of

April 30, 2026

23 more funds behind a free account

See every fund holding Actuate Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AG Aaron G.L. Fletcher 5%+ holder 13D · 49.8%	10.3M	42.75%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company42.750% Disclosed stake13D · 49.8% View the 13D/G filing →
BA Bios Advisors GP, LLC 5%+ holder 13D · 49.5%	10.2M	42.44%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company42.440% Disclosed stake13D · 49.5% View the 13D/G filing →

Aaron G.L. Fletcher

5%+ holder13D · 49.8%

10.3M

% of company

42.75%

Change vs last qtr

—

Held since

—

Bios Advisors GP, LLC

5%+ holder13D · 49.5%

10.2M

% of company

42.44%

Change vs last qtr

—

Held since

—

22 more holders behind a free account

See every insider and 5%+ holder of Actuate Therapeutics Inc.

Comments